Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

SU 9516

CDK/cyclin inhibitor
ALX-270-400-M005 5 mg 104.00 USD
ALX-270-400-M025 25 mg 354.00 USD
Do you need bulk/larger quantities?
Cell permeable, potent, selective and ATP-competitive inhibitor of CDK2/cyclin A (IC50=22nM), CDK1/cyclin B (IC50=40nM) and CDK4/cyclin D1 (IC50=200nM). Has no effect on the activity of PKC, p38, PDGFRβ and EGFR (IC50>10µM). Displays anti-proliferative and pro-apoptotic properties in tumor cells. Inhibits proliferation of growth factor-stimulated colon carcinoma cells by binding to CDK2 and thus preventing the phosphorylation of pRb and its dissociation from E2F.

Product Specification

Alternative Name:3-[1-(3H-Imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one
Purity:≥95% (HPLC)
Appearance:Yellow to orange solid.
Solubility:Soluble in DMSO (10mg/ml).
Shipping:Shipped on Blue Ice
Long Term Storage:+4°C
Handling:Protect from light. Packaged under inert gas.
Please mouse over

Product Literature References

Novel pyrrolyllactone and pyrrolyllactam indolinones as potent cyclin-dependent kinase 2 inhibitors: X. Li, et al.; Bioorg. Med. Chem. Lett. 13, 1939 (2003), Abstract;
SU9516: biochemical analysis of cdk inhibition and crystal structure in complex with cdk2: D.J. Moshinsky, et al.; BBRC 310, 1026 (2003), Abstract;
SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cells: B. Yu, et al.; Biochem. Pharmacol. 64, 1091 (2002), Abstract;
A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells: M.E. Lane, et al.; Cancer Res. 61, 6170 (2001), Abstract;

Related Literature

Integrated solutions for screening Wnt regulators
Integrated solutions for screening Wnt regulators
Download as PDF

All new literature pieces

Recommend this page

For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2020 Enzo Life Sciences, Inc.,